Neuroscientific Biopharmaceuticals (NSB)

Executive Summary

Neuroscientific Biopharmaceuticals Ltd (ASX:NSB) is an Australian clinical-stage biotech developing patented mesenchymal stem cell (MSC) therapies for immune-mediated inflammatory diseases. Its proprietary StemSmart™ platform enables GMP-grade manufacturing of MSCs with enhanced anti-inflammatory properties. The lead program targets refractory and fistulising Crohn’s disease, a high unmet need, with a Phase 2 trial underway. The company also plans to expand into lung and kidney indications, leveraging its technology across multiple inflammatory disorders. Despite the typical risks of Phase 2 development, Neuroscientific benefits from a strong balance sheet and a strategic manufacturing partnership, positioning it to deliver key clinical milestones. The company’s conviction is underpinned by the differentiated mechanism of action and the scalability of its StemSmart platform. The upcoming Phase 2 data readout in Crohn’s disease will be a critical value inflection point, potentially de-risking the platform for other indications. With a well-capitalized position and a focus on cost-efficient development, Neuroscientific represents a speculative but potentially rewarding opportunity in the regenerative medicine space, subject to clinical execution and market conditions.

Upcoming Catalysts (preview)

• Q3 2026Top-line Phase 2 data in fistulising Crohn’s disease45% success
• Q4 2026Initiation of Phase 2 trial in lung indication (e.g., COPD or IPF)30% success
• H1 2026Licensing or partnership deal for non-Crohn’s indications40% success